After phase I studies, one set of these previously tested cases commenced a phase II research work to assess Sunitinib usage in combination with traditionally used chemotherapy (Cytosine arabinoside (Ara-C)/Daunorubicin induction (7:3) followed by three cycles of intermediate-dose Ara-C) in FLT3-mutated AML cases higher than six decades in age. Here, FLT3 is linked to acute myeloid leukemia.